Pharmacotherapy for borderline personality disorder: NICE guideline

Authors:
  • TKTim Kendall
    Tim Kendall
  • RBRachel Burbeck
    Rachel Burbeck
  • ABAnthony Bateman
    Anthony Bateman

Abstract
There are a number of reasons for the disparity. First, we did not consider the evidence from some studies to be usable.3–7 These trials tended to find large effect sizes favouring treatment compared with effect sizes from other trials. Following further investigation, we considered this evidence for topiramate, lamotrigine or aripiprazole to be unreliable and excluded the trials from our analysis (see p. 218 of the full guideline2).

This publication has 9 references indexed in Scilit: